ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vismodegib, quantity: 150 mg - capsule, hard - excipient ingredients: purified talc; iron oxide red; gelatin; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; iron oxide black; shellac; lactose monohydrate; povidone; magnesium stearate; sodium lauryl sulfate - erivedge is indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

कनाडा - अंग्रेज़ी - Health Canada

bayer inc - levonorgestrel - insert (extended-release) - 13.5mg - levonorgestrel 13.5mg - contraceptives

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. ortho micronor® tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease - it's best to take your first pop on the first day of your menstrual period (day 1 start). if you use a day 1 start, you are protected from becoming pregnant as soon as you take your first pill. - if you decide to tak

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. method (1) % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * typical use † (2) perfect use ‡ (3) (4) no method§ 85 85 spermicides¶ 28 18 42 fertility awareness-based methods 24 47    standard days method# 5       two day method# 4    ovulation method# 3    symptothermal# 0.4 withdrawal 22 4 46 sponge 36    parous women 24 20    nulliparous women 12 9 condomÞ    female (fc) 21 5 41    male 18 2 43 diaphragmß 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine co

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

northstar rx llc - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. table 1: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. united states.  5  4  3  0.4  24  12  20  9  21  18  5  2  41  43  0.8  0.2  0.6  0.2  78  80 emergency contraception: emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.9 (see chapter 6.) lactational amenorrhea method: lam is a highly effective, temporary method of contraception.10 (see chapter 18.) source: truss

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. errin ® tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - 1.         indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2.         efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. emergency contraception: emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.9 (see chapter 6.). lactational amenorrhea method: lam is a highly effective, temporary method of contraception.10 (see chapter 18.) source: trussell j. contraceptive efficacy. in hatcher ra, trussell j, nelson al, cates w, kowal d, policar m. contraceptive techology: twentieth revised edition. new york ny: ardent media, 2011. notes: 1   among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom, the oral contraceptive pill, and depo-provera are taken from the 1995 national survey of family growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods. 2   among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. see the text for the derivation of the estimate for each method. 3   among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. 4   the percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within 1 year. this estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5    foams, creams, gels, vaginal suppositories, and vaginal film. 6   the ovulation and two day methods are based on evaluation of cervical mucus. the standard days method avoids intercourse on cycle days 8 through 19. the symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day. 7    without spermicides. 8    with spermicidal cream or jelly. 9   ella, plan b one-step and next choice are the only dedicated products specifically marketed for emergency contraception. the label for plan b one-step (one dose is 1 white pill) says to take the pill within 72 hours after unprotected intercourse. research has shown that all of the brands listed here are effective when used within 120 hours after unprotected sex. the label for next choice (one dose is 1 peach pill) says to take 1 pill within 72 hours after unprotected intercourse and another pill 12 hours later. research has shown that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 hours after unprotected sex. the fda has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: ogestrel (1 dose is 2 white pills), nordette (1 dose is 4 light-orange pills), cryselle, levora, low-ogestrel, lo/ovral, or quasence (1 dose is 4 white pills), jolessa, portia, seasonale or trivora (1 dose is 4 pink pills), seasonique (1 dose is 4 light-blue-green pills), enpresse (one dose is 4 orange pills), lessina (1 dose is 5 pink pills), aviane or loseasonique (one dose is 5 orange pills), lutera or sronyx (one dose is 5 white pills), and lybrel (one dose is 6 yellow pills).      10  however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. jencycla tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease